Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8627074rdf:typepubmed:Citationlld:pubmed
pubmed-article:8627074lifeskim:mentionsumls-concept:C0026946lld:lifeskim
pubmed-article:8627074lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:8627074lifeskim:mentionsumls-concept:C0376152lld:lifeskim
pubmed-article:8627074lifeskim:mentionsumls-concept:C0332835lld:lifeskim
pubmed-article:8627074lifeskim:mentionsumls-concept:C0205281lld:lifeskim
pubmed-article:8627074lifeskim:mentionsumls-concept:C0338196lld:lifeskim
pubmed-article:8627074lifeskim:mentionsumls-concept:C0920321lld:lifeskim
pubmed-article:8627074pubmed:issue5lld:pubmed
pubmed-article:8627074pubmed:dateCreated1996-6-21lld:pubmed
pubmed-article:8627074pubmed:abstractTextAmphotericin B colloidal dispersion (ABCD; Amphocil) was evaluated in a phase I dose-escalation study in 75 marrow transplant patients with invasive fungal infections (primarily Aspergillus or Candida species) to determine the toxicity profile, maximum tolerated dose, and clinical response. Escalating doses of 0.5-8.0 mg/kg in 0.5-mg/kg/patient increments were given up to 6 weeks. No infusion-related toxicities were observed in 32% of the patients; 52% had grade 2 and 5% had grade 3 toxicity. No appreciable renal toxicity was observed at any dose level. The estimated maximum tolerated dose was 7.5 mg/kg, defined by rigors and chills and hypotension in 3 of 5 patients at 8.0 mg/kg. The complete or partial response rate across dose levels and infection types was 52%. For specific types of infections, 53% of patients with fungemia had complete responses, and 52% of patients with pneumonia had complete or partial responses. ABCD was safe at doses to 7.5 mg/kg and had tolerable-infusion-related toxicity and demonstrable antifungal activity.lld:pubmed
pubmed-article:8627074pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8627074pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8627074pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8627074pubmed:languageenglld:pubmed
pubmed-article:8627074pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8627074pubmed:citationSubsetAIMlld:pubmed
pubmed-article:8627074pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8627074pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8627074pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8627074pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8627074pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8627074pubmed:statusMEDLINElld:pubmed
pubmed-article:8627074pubmed:monthMaylld:pubmed
pubmed-article:8627074pubmed:issn0022-1899lld:pubmed
pubmed-article:8627074pubmed:authorpubmed-author:MamelokR DRDlld:pubmed
pubmed-article:8627074pubmed:authorpubmed-author:BowdenR ARAlld:pubmed
pubmed-article:8627074pubmed:authorpubmed-author:van BurikJ...lld:pubmed
pubmed-article:8627074pubmed:authorpubmed-author:BEANB CBClld:pubmed
pubmed-article:8627074pubmed:authorpubmed-author:GooleyTTlld:pubmed
pubmed-article:8627074pubmed:issnTypePrintlld:pubmed
pubmed-article:8627074pubmed:volume173lld:pubmed
pubmed-article:8627074pubmed:ownerNLMlld:pubmed
pubmed-article:8627074pubmed:authorsCompleteYlld:pubmed
pubmed-article:8627074pubmed:pagination1208-15lld:pubmed
pubmed-article:8627074pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:8627074pubmed:meshHeadingpubmed-meshheading:8627074-...lld:pubmed
pubmed-article:8627074pubmed:meshHeadingpubmed-meshheading:8627074-...lld:pubmed
pubmed-article:8627074pubmed:meshHeadingpubmed-meshheading:8627074-...lld:pubmed
pubmed-article:8627074pubmed:meshHeadingpubmed-meshheading:8627074-...lld:pubmed
pubmed-article:8627074pubmed:meshHeadingpubmed-meshheading:8627074-...lld:pubmed
pubmed-article:8627074pubmed:meshHeadingpubmed-meshheading:8627074-...lld:pubmed
pubmed-article:8627074pubmed:meshHeadingpubmed-meshheading:8627074-...lld:pubmed
pubmed-article:8627074pubmed:meshHeadingpubmed-meshheading:8627074-...lld:pubmed
pubmed-article:8627074pubmed:meshHeadingpubmed-meshheading:8627074-...lld:pubmed
pubmed-article:8627074pubmed:meshHeadingpubmed-meshheading:8627074-...lld:pubmed
pubmed-article:8627074pubmed:meshHeadingpubmed-meshheading:8627074-...lld:pubmed
pubmed-article:8627074pubmed:meshHeadingpubmed-meshheading:8627074-...lld:pubmed
pubmed-article:8627074pubmed:meshHeadingpubmed-meshheading:8627074-...lld:pubmed
pubmed-article:8627074pubmed:year1996lld:pubmed
pubmed-article:8627074pubmed:articleTitlePhase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant.lld:pubmed
pubmed-article:8627074pubmed:affiliationFred Hutchinson Cancer Research Center, Seattle, WA 98104-2092, USA.lld:pubmed
pubmed-article:8627074pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8627074pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:8627074pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:8627074pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:8627074pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8627074lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8627074lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8627074lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8627074lld:pubmed